Why under-40s will be offered alternative to Oxford-AstraZeneca vaccine
Experts say potential blood clot risk vs. benefits of the Covid jab is ‘more finely balanced’ for younger adults
People aged under 40 are to be offered an alternative to the Oxford-AstraZeneca coronavirus vaccine as a precaution against the possible risk of blood clots, UK health officials have announced.
The change in guidance from the Joint Committee on Vaccination and Immunisation (JCVI) “marks an extension to existing guidance” that all under-30s in the UK should be offered a choice over which Covid-19 vaccine they receive, Sky News reports.
According to latest data from the Medicines and Healthcare products Regulatory Agency (MHRA), a total of 242 clotting cases and 49 related deaths have been recorded among recipients of around 28.5 million doses of the vaccine administered so far. That equates to an incidence rate of 10.5 per million doses, and about one in a million for a second dose.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
However, the risk of clotting “is slightly higher in younger age groups”, says the BBC. And with younger people less likely to die or suffer extreme symptoms as a result of infection with the coronavirus, the MHRA has concluded that the potential benefits vs. risks is “more finely balanced” among younger groups.
“Low levels of coronavirus” across the country and “the availability of alternative vaccines” has also informed the decision, the broadcaster adds.
JCVI chair Professor Wei Shen Lim has emphasised that "safety remains our number one priority”.
“As Covid-19 rates continue to come under control, we are advising that adults aged 18 to 39 years with no underlying health conditions are offered an alternative to the Oxford-AstraZeneca vaccine, if available and if it does not cause delays in having the vaccine,” he said.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Underlining the safety message, MHRA chief executive Dr June Raine said the benefits of the Oxford jab continued to outweigh the risks for the “vast majority of people”. But while “the balance of benefits and risks is very favourable for older people”, it “is more finely balanced for younger people”, she added.
However, some under-40s may still be offered the Oxford vaccine as it is “as it is easier to both transport and store, making it more practical than the alternatives”, the BBC reports. The JCVI guidance states that “an alternative jab should only be given where it does not cause a major delay in immunisation”.
Under the JCVI’s timetable for the national Covid jabs rollout, all adults in the UK are to be offered a first dose by the end of July.
-
Why Bhutan hopes tourists will put a smile back on its face
Under The Radar The 'kingdom of happiness' is facing economic problems and unprecedented emigration
By Chas Newkey-Burden, The Week UK Published
-
7 beautiful towns to visit in Switzerland during the holidays
The Week Recommends Find bliss in these charming Swiss locales that blend the traditional with the modern
By Catherine Garcia, The Week US Published
-
The Week contest: Werewolf bill
Puzzles and Quizzes
By The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published